TY - JOUR
T1 - 1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration
AU - MASCOT
AU - REMEDEE investigators (Appendix I in the Supplementary material)
AU - Chandrasekhar, Jaya
AU - Kalkman, Deborah N.
AU - Aquino, Melissa B.
AU - Sartori, Samantha
AU - Hájek, Petr
AU - Atzev, Borislav
AU - Hudec, Martin
AU - Ong, Tiong Kiam
AU - Mates, Martin
AU - Borisov, Borislav
AU - Warda, Hazem M.
AU - den Heijer, Peter
AU - Wojcik, Jaroslaw
AU - Iñiguez, Andrés
AU - Coufal, Zdeněk
AU - Khashaba, Ahmed
AU - Schee, Alexandr
AU - Munawar, Muhammad
AU - Gerber, Robert T.
AU - Yan, Bryan P.
AU - Tejedor, Paula
AU - Kala, Petr
AU - Liew, Houng Bang
AU - Lee, Michael
AU - Baber, Usman
AU - Vogel, Birgit
AU - Dangas, George D.
AU - Colombo, Antonio
AU - de Winter, Robbert J.
AU - Mehran, Roxana
PY - 2020/5/15
Y1 - 2020/5/15
N2 - Background: The COMBO drug-eluting stent combines sirolimus-elution from a biodegradable polymer with an anti-CD34+ antibody coating for early endothelialization. Objective: We investigated for geographical differences in outcomes after percutaneous coronary intervention (PCI) with the COMBO stent among Asians and Europeans. Methods: The COMBO Collaboration is a pooled patient-level analysis of the MASCOT and REMEDEE registries of all-comers undergoing attempted COMBO stent PCI. The primary outcome was 1-year target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction (TV-MI) and target lesion revascularization (TLR). Results: This study included 604 Asians (17.9%) and 2775 Europeans (82.1%). Asians were younger and included fewer females, with a higher prevalence of diabetes mellitus but lower prevalence of other comorbidities than Europeans. Asians had a higher prevalence of ACC/AHA C type lesions and received longer stent lengths. More Asians than Europeans were discharged on clopidogrel (86.5% vs 62.8%) rather than potent P2Y12 inhibitors. One-year TLF occurred in 4.0% Asians and 4.1% of Europeans, p = 0.93. The incidence of cardiac death was higher in Asians (2.8% vs. 1.3%, p = 0.007) with similar rates of TV-MI (1.5% vs. 1.2%, p = 0.54) and definite stent thrombosis (0.3% vs. 0.5%, p = 0.84) and lower incidence of TLR than Europeans (1.0% vs. 2.5%, p = 0.025). After adjustment, differences for cardiac death and TLR were no longer significant. Conclusions: In the COMBO collaboration, although 1-year TLF was similar regardless of geography, Asians experienced higher rates of cardiac death and lower TLR than Europeans, while incidence of TV-MI and ST was similar in both regions. Adjusted differences did not reach statistical significance. Clinicaltrial.gov identifier-numbers: NCT01874002 (REMEDEE Registry), NCT02183454 (MASCOT registry).
AB - Background: The COMBO drug-eluting stent combines sirolimus-elution from a biodegradable polymer with an anti-CD34+ antibody coating for early endothelialization. Objective: We investigated for geographical differences in outcomes after percutaneous coronary intervention (PCI) with the COMBO stent among Asians and Europeans. Methods: The COMBO Collaboration is a pooled patient-level analysis of the MASCOT and REMEDEE registries of all-comers undergoing attempted COMBO stent PCI. The primary outcome was 1-year target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction (TV-MI) and target lesion revascularization (TLR). Results: This study included 604 Asians (17.9%) and 2775 Europeans (82.1%). Asians were younger and included fewer females, with a higher prevalence of diabetes mellitus but lower prevalence of other comorbidities than Europeans. Asians had a higher prevalence of ACC/AHA C type lesions and received longer stent lengths. More Asians than Europeans were discharged on clopidogrel (86.5% vs 62.8%) rather than potent P2Y12 inhibitors. One-year TLF occurred in 4.0% Asians and 4.1% of Europeans, p = 0.93. The incidence of cardiac death was higher in Asians (2.8% vs. 1.3%, p = 0.007) with similar rates of TV-MI (1.5% vs. 1.2%, p = 0.54) and definite stent thrombosis (0.3% vs. 0.5%, p = 0.84) and lower incidence of TLR than Europeans (1.0% vs. 2.5%, p = 0.025). After adjustment, differences for cardiac death and TLR were no longer significant. Conclusions: In the COMBO collaboration, although 1-year TLF was similar regardless of geography, Asians experienced higher rates of cardiac death and lower TLR than Europeans, while incidence of TV-MI and ST was similar in both regions. Adjusted differences did not reach statistical significance. Clinicaltrial.gov identifier-numbers: NCT01874002 (REMEDEE Registry), NCT02183454 (MASCOT registry).
KW - Anti-CD34+ antibody coating
KW - COMBO stent
KW - Endothelial progenitor cell capture
KW - Geographical differences
KW - Percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85080039817&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ijcard.2020.01.045
DO - https://doi.org/10.1016/j.ijcard.2020.01.045
M3 - Article
C2 - 32111358
SN - 0167-5273
VL - 307
SP - 17
EP - 23
JO - International journal of cardiology
JF - International journal of cardiology
ER -